Abstract PR07: Phase II Trial of the MEK 1/2 inhibitor selumetinib (AZD6344, ARRY-142886 hydrogen sulphate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN)

Phase Ii Trial ◽

Neurofibromatosis Type ◽

Plexiform Neurofibromas ◽

Hydrogen Sulphate

Phase II trial of the MEK1/2 inhibitor selumetinib (AZD6244) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps2596 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS2596-TPS2596 ◽

Cited By ~ 1

Author(s):

Diana Bradford ◽

Patricia Whitcomb ◽

Eva Dombi ◽

Alice P. Chen ◽

Andrea Baldwin ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Neurofibromatosis Type ◽

Abstract CT233: Treatment of neurofibromatosis type 1 (NF1)-related plexiform neurofibromas (PN) with cabozantinib (XL184): A Neurofibromatosis Clinical Trials Consortium Phase II trial

10.1158/1538-7445.am2019-ct233 ◽

2019 ◽

Author(s):

Chie-Schin Shih ◽

Jaishri Blakeley ◽

D. Wade Clapp ◽

Amy E. Armstrong ◽

Pam Wolters ◽

...

Keyword(s):

Clinical Trials ◽

Phase Ii ◽

Phase Ii Trial ◽

Neurofibromatosis Type ◽

Abstract CT233: Treatment of neurofibromatosis type 1 (NF1)-related plexiform neurofibromas (PN) with cabozantinib (XL184): A Neurofibromatosis Clinical Trials Consortium Phase II trial

10.1158/1538-7445.sabcs18-ct233 ◽

2019 ◽

Author(s):

Chie-Schin Shih ◽

Jaishri Blakeley ◽

D. Wade Clapp ◽

Amy E. Armstrong ◽

Pam Wolters ◽

...

Keyword(s):

Clinical Trials ◽

Phase Ii ◽

Phase Ii Trial ◽

Neurofibromatosis Type ◽

Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas

Pediatric Blood & Cancer ◽

10.1002/pbc.25041 ◽

2014 ◽

Vol 61 (9) ◽

pp. 1598-1602 ◽

Cited By ~ 37

Author(s):

Brigitte C. Widemann ◽

Dusica Babovic-Vuksanovic ◽

Eva Dombi ◽

Pamela L. Wolters ◽

Stewart Goldman ◽

...

Keyword(s):

Young Adults ◽

Phase Ii ◽

Phase Ii Trial ◽

Neurofibromatosis Type ◽

Plexiform Neurofibromas ◽

Children And Young Adults

Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas

Neuro-Oncology ◽

10.1093/neuonc/now158 ◽

2016 ◽

pp. now158 ◽

Cited By ~ 5

Author(s):

Regina I. Jakacki ◽

Eva Dombi ◽

Seth M. Steinberg ◽

Stewart Goldman ◽

Mark W. Kieran ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Young Patients ◽

Neurofibromatosis Type ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Plexiform Neurofibromas ◽

Pegylated Interferon Alfa

Phase II trial of pirfenidone in adults with neurofibromatosis type 1

Neurology ◽

10.1212/01.wnl.0000243231.12248.67 ◽

2006 ◽

Vol 67 (10) ◽

pp. 1860-1862 ◽

Cited By ~ 47

Author(s):

D. Babovic-Vuksanovic ◽

K. Ballman ◽

V. Michels ◽

P. McGrann ◽

N. Lindor ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Neurofibromatosis Type

NFM-01. NF105: A PHASE II PROSPECTIVE STUDY OF CABOZANTINIB (XL184) FOR PLEXIFORM NEUROFIBROMAS IN SUBJECTS WITH NEUROFIBROMATOSIS TYPE 1: A NEUROFIBROMATOSIS CLINICAL TRIAL CONSORTIUM (NFCTC) STUDY

Neuro-Oncology ◽

10.1093/neuonc/noy059.510 ◽

2018 ◽

Vol 20 (suppl_2) ◽

pp. i142-i142

Author(s):

Chie-Schin Shih ◽

Jaishri Blakely ◽

Wade Clapp ◽

Pam Wolters ◽

Eva Dombi ◽

...

Keyword(s):

Clinical Trial ◽

Prospective Study ◽

Phase Ii ◽

Neurofibromatosis Type ◽

SPRINT: Phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.10503 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 10503-10503 ◽

Cited By ~ 11

Author(s):

Andrea M. Gross ◽

Pamela Wolters ◽

Andrea Baldwin ◽

Eva Dombi ◽

Michael J. Fisher ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Study ◽

Neurofibromatosis Type ◽

NFM-07. SPRINT: PHASE II STUDY OF THE MEK 1/2 INHIBITOR SELUMETINIB (AZD6244, ARRY-142886) IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND INOPERABLE PLEXIFORM NEUROFIBROMAS (PN)

Neuro-Oncology ◽

10.1093/neuonc/noy059.515 ◽

2018 ◽

Vol 20 (suppl_2) ◽

pp. i143-i144 ◽

Cited By ~ 2

Author(s):

Andrea Gross ◽

Pamela Wolters ◽

Andrea Baldwin ◽

Eva Dombi ◽

Michael J Fisher ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Study ◽

Neurofibromatosis Type ◽

Phase II Study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps10586 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS10586-TPS10586

Author(s):

Andrea M Gross ◽

Andrea Baldwin ◽

Eva Dombi ◽

Pamela Wolters ◽

Patricia Whitcomb ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Study ◽

Neurofibromatosis Type ◽